Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03926143 · FLOW

Participant flow

A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies · Source last updated 2023-08-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Adult participants with solid tumors who received anetumab-ravtansine treatment as monotherapy, or in combination with gemcitabine in an applicable Bayer-sponsored anetumab ravtansine study. 8 participants received anetumab ravtansine monotherapy and 1 participant received anetumab ravtansine in combination with gemcitabine. Pooled results were reported.
    id
    FG000
    title
    Anetumab Ravtansine
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Physician Decision
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Subject decision: Covid-19 Pandemic related
    3. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Adverse Event
    4. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Progressive disease
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        9
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        9
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
A total of 10 participants were screened in this study; of whom 9 participants started study treatment and 1 participant was a screening failure.
recruitment Details
The study was conducted at 7 study centers in 4 countries worldwide between 03-Jun-2019 (first participant first visit) and 18-May-2022 (last participant last visit). Entering participants had to have been treated with anetumab ravtansine in an applicable Bayer sponsored anetumab ravtansine parent study.
Complete source fields
groups
  1. description
    Adult participants with solid tumors who received anetumab-ravtansine treatment as monotherapy, or in combination with gemcitabine in an applicable Bayer-sponsored anetumab ravtansine study. 8 participants received anetumab ravtansine monotherapy and 1 participant received anetumab ravtansine in combination with gemcitabine. Pooled results were reported.
    id
    FG000
    title
    Anetumab Ravtansine
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Physician Decision
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Subject decision: Covid-19 Pandemic related
    3. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Adverse Event
    4. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Progressive disease
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        9
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        9
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
A total of 10 participants were screened in this study; of whom 9 participants started study treatment and 1 participant was a screening failure.
recruitment Details
The study was conducted at 7 study centers in 4 countries worldwide between 03-Jun-2019 (first participant first visit) and 18-May-2022 (last participant last visit). Entering participants had to have been treated with anetumab ravtansine in an applicable Bayer sponsored anetumab ravtansine parent study.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice